Zerlasiran was found to be well tolerated and no significant safety concerns were observed. Credit: Good dreams - Studio via ...

"AHA 2024: Muvalaplin shows promising Phase II results for elevated serum lipoprotein (a)" was originally created and ...

A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...

At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a "major new path" of cardiovascular ...

Data reveal a strong association between non–high-density lipoprotein (non-HDL) cholesterol to HDL cholesterol ratio and ...

In terms of lipid profiles, the study indicated that GERD was associated with increased levels of low-density lipoprotein ...

While having HDL levels above 60 mgdL is often seen as a sign of good health it’s not a standalone indicator Read ahead to ...

The FDA rejected an application from Astellas seeking to change the prescribing label for its eye drug Izervay to allow less ...

Excess cholesterol is known to form artery-clogging plaques that can lead to stroke, arterial disease, heart attack, and more, making it the focus of many heart health campaigns.

On Monday, Eli Lilly And Co (NYSE:LLY) announced Phase 2 results for muvalaplin, an investigational once-daily, orally ...

American Heart Association Scientific Sessions 2024, Abstract 4171286 - The oral medication muvalaplin may safely lower high ...

Researchers at University of Tsukuba analyzed data from middle-aged workers who had received Specific Health Guidance—a ...